Bradley J. Monk, MD
The treatment of women with advanced-stage epithelial ovarian cancer (EOC) is aggressive surgical cytoreduction and platinum-based combination chemotherapy. The timing and the extent of surgery have direct implications on the selection of subsequent treatment of patients with EOC. Frontline chemotherapeutic regimens have evolved through a series of large multi-institutional randomized clinical trials that led to a combination of a platinum with a taxane. Subsequent clinical trials have focused on maximizing the benefit of this combination through different dosing schedules, routes of administration, durations of treatment, and combinations with other agents, including biologics and maintenance therapy.
... to read the full story